ClinicalTrials.gg
CompletedNCT04557189Updated Apr 21, 2023Results posted

A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery

A Phase 2 interventional study of TAK-951 and Ondansetron in Postoperative Nausea and Vomiting (PONV), sponsored by Takeda. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-21.

Sponsored by Takeda · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 42 studies testing ondansetron in Postoperative Nausea and Vomiting — 2 open to participants now, 3 under way, none of them phase 3. Ondansetron · Postoperative Nausea and Vomiting.

Enrollment
32nd of 42
89 · median 121
Started
2020
with 3 others
Phase 2
3 of 42
none open now
Registered
26th of 42
by date

Among the 42 studies testing ondansetron in Postoperative Nausea and Vomiting, this one is the 32nd largest by enrollment, is one of 4 that started in 2020, is one of 3 in phase 2, and was the 26th registered.

Postoperative Nausea and Vomiting

638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.

Browse Postoperative Nausea and Vomiting studies →

Open to participants now

2 of the 42 studies testing ondansetron in Postoperative Nausea and Vomiting are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ondansetron

Ondansetron: first FDA approval 1991 (ZOFRAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 65 Postoperative Nausea and Vomiting studies recruiting now, 22 (34%) set no upper age limit and 37 (57%) stop at 75 or younger; 14 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing ondansetron in Postoperative Nausea and Vomiting, or all of them as a file.
02

Study summary

Some adults are at a higher risk of feeling sick (nausea) or being sick (vomiting) after they have surgery. In this study, these adults will have planned surgery. The main aim of this study is to learn if TAK-951 stops these adults from getting nausea or vomiting after surgery. This will be compared with another medicine called ondansetron. Another aim is to check for side effects from the study medicines.

Before surgery, the study doctor will check who can take part in this study. Those who can take part will be picked for either Treatment Group A or Treatment Group B by chance.

  • Treatment Group A: Just before surgery, participants will receive a placebo slowly through a vein (infusion). Just before the end of the surgery, they will receive TAK-951 as an injection under the skin.
  • Treatment Group B: Just before surgery, participants will receive ondansetron slowly through a vein (infusion). Just before the end of the surgery, they will receive a placebo as an injection under the skin. In this study, a placebo will look like TAK-951 but will not have any medicine in it.

Participants will not know which study medicines they received, or in which order, nor will their study doctors or surgeons. This is to help make sure the results are more reliable.

Participants will stay in the hospital for 24 hours after their surgery so that the study doctors can check for nausea and vomiting. The study doctors will also check for side effects from the study medicines.

Participants will visit the hospital for a check-up 14 days later.

Read the detailed description

The drug being tested in this study is called TAK-951. TAK-951 is being tested for prophylaxis for postoperative nausea and vomiting in high-risk participants.

The study will enroll a maximum of 160 patients, to allow a sample size of up to approximately 100 participants who have received both doses of Double-blind study drug/matching placebo. Participants will be randomly assigned in a 1:1 ratio to either Treatment Group A or Treatment Group B which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

  • Treatment Group A: Just before surgery, participants will receive a placebo slowly through a vein (infusion). Just before the end of the surgery, they will receive TAK-951 as an injection under the skin.
  • Treatment Group B: Just before surgery, participants will receive ondansetron slowly through a vein (infusion). Just before the end of the surgery, they will receive a placebo as an injection under the skin. In this study, a placebo will look like TAK-951 but will not have any medicine in it.

This trial will be conducted in the United States. The overall time to participate in the study from the time of surgery to completion is approximately 14 days. Participants will make multiple visits to the clinic and will be contacted by telephone after receiving their last dose of the drug for a follow-up assessment.

03

Conditions studied

  • Postoperative Nausea and Vomiting (PONV)

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants undergoing elective surgery under general anesthesia, expected to last for at least 1 hour from induction of anesthesia to wound closure.
  2. Participants are expected to require or have agreed to stay, at least 1 overnight in the hospital.
  3. Participants (ASA) physical status is ASA I-III.
  4. Participants with 3 or more Apfel risk factors defined as:

    1. Female sex.
    2. Nonsmoking status (never smoked or stopped smoking ≥12 months ago).
    3. History of PONV or motion sickness.
    4. Planned use of postoperative opioid analgesics.

Exclusion criteria

Exclusion Criteria:

  1. Participants who are expected to remain intubated post-anesthesia.
  2. Participants who experience nausea or vomiting within 24 hours before surgery or are diagnosed with gastroparesis, cyclic vomiting syndrome, or other condition associated with acute or chronic nausea and vomiting.
  3. Participants who have received, or are expected to receive, any excluded drug preoperatively within 24 hours before induction, during surgery, or within 24 hours after surgery.
  4. Participants scheduled to receive neuraxial anesthesia (e.g., epidural, spinal, or caudal anesthesia), regional blocks, or total IV anesthesia, and/or planned to receive different drugs for premedication, induction, maintenance, or reversal of anesthesia than those specified in the protocol.
  5. Participants who have an allergy or to the recommended and available rescue therapy for the treatment of PONV.
  6. Circumstance that, in the investigator's opinion, make participation in this clinical study inappropriate.
  7. Participants found at the screening to have a with Fridericia correction method (QTcF) ≥450 msec or other factors that increase the risk of QT prolongation or arrhythmic events. Assessments showing bundle branch block and a prolonged QTcF should be discussed with the study monitor and the sponsor for potential inclusion.
  8. Participants who have a direct family history of premature sudden death or channelopathy, personal history of Brugada syndrome (right bundle branch block pattern with ST elevation in leads V1-V3), long QT, short QT, arrhythmogenic right ventricular dysplasia, hypertrophic cardiomyopathy or catecholaminergic polymorphic ventricular tachycardia (VT).
  9. Participants who have had 3 incidents of vasovagal syncope within the last 5 years.
  10. Participants with an average heart rate (HR) \<55 or >100 bpm or systolic blood pressure (SBP) \<90 mm Hg or Diastolic blood pressure (DBP) \<60 mm Hg during screening or prior to randomization on the day of surgery.
  11. Participants with a abnormality indicative of acute cardiac instability as determined by the investigator at screening, including more than first-degree atrioventricular block, nonsustained or sustained VT, or ECG changes consistent with acute myocardial ischemia or infarction.
  12. Participants with a history of acute myocardial ischemia within the last 12 months.
  13. Participants receiving beta-blockers chronically or between screening and surgery that cannot be safely withheld on the day of surgery in the investigator's judgment. Participants receiving certain other cardiovascular medications, such as vasodilators for hypertension, chronically or between screening and surgery that in the investigator's judgment cannot be adequately managed in the perioperative setting considering the potential vasodilatory effects of TAK-951 and anesthesia standard of care. The investigators must consult with the medical monitor regarding the eligibility of participants who are receiving beta-blockers, vasodilators, and other classes of medications that act on HR or BP.
  14. Participants with (ALT) or aspartate aminotransferase (AST) >2 times the (ULN) or total >1.5 times the ULN.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Ondansetron 4 mg IV

    Participants received prophylaxis with ondansetron 4 mg, intravenously (IV) immediately before induction and TAK-951 placebo subcutaneously (SC) approximately 30 to 45 minutes before the end of surgery (wound closure).

    Drug: Ondansetron · Drug: TAK-951 Placebo

  • Experimental
    TAK-951 4 mg SC

    Participants received prophylaxis with ondansetron placebo IV immediately before induction and TAK 951 4 mg, SC, approximately 30 to 45 minutes before the end of surgery (wound closure).

    Drug: TAK-951 · Drug: Ondansetron Placebo

Interventions

  • TAK-951 SC injection

  • Ondansetron IV injection

  • DrugOndansetron Placebo

    Ondansetron placebo-matching IV injection

  • DrugTAK-951 Placebo

    TAK-951 placebo-matching SC injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Complete Response in the Immediate Postoperative Period

    Percentage of participants with complete response, defined as no emesis (vomiting or retching) and no need for rescue therapy (indicated if vomiting/retching and/or nausea score ≥4 or upon participant's request) were reported. The severity of nausea was scored using a self-reported, 11-point numerical Verbal Rating Scale (VRS), where 0 represents no nausea and 10 represents the worst nausea possible. Significant nausea was defined as a VRS score ≥4. Percentages are rounded off to whole number at the nearest single decimal.

    Time frame: 6 hours post-surgery (Day 1)

Secondary outcomes

  1. Percentage of Participants With Complete Response Within 24 Hours Post-Surgery

    Percentage of participants with complete response, defined as no emesis (vomiting or retching) and no need for rescue therapy (indicated if vomiting/retching and/or nausea score ≥4 or upon participant's request) were reported. The severity of nausea was scored using a self-reported, 11-point numerical Verbal Rating Scale (VRS), where 0 represents no nausea and 10 represents the worst nausea possible. Significant nausea was defined as a VRS score ≥4. Percentages are rounded off to whole number at the nearest single decimal.

    Time frame: Within 24 hours post-surgery (up to Day 2)

  2. Percentage of Participants With Emesis in the First 6 Hours Post-Surgery

    Percentage of participants with emesis, defined as vomiting (the forceful discharge of even the smallest amount of stomach contents) or retching (the same muscular movements as vomiting but without expulsion of stomach contents) were reported. Percentages are rounded off to whole number at the nearest single decimal.

    Time frame: Within 6 hours post-surgery (Day 1)

  3. Percentage of Participants With Emesis Within 24 Hours Post-Surgery

    Percentage of participants with emesis, defined as vomiting (the forceful discharge of even the smallest amount of stomach contents) or retching (the same muscular movements as vomiting but without expulsion of stomach contents) were reported. Percentages are rounded off to whole number at the nearest single decimal.

    Time frame: Within 24 hours post-surgery (up to Day 2)

  4. Percentage of Participants With Absence of Nausea in the First 6 Hours Post-Surgery

    Percentage of participants without nausea, defined as urge to vomit without the presence of expulsive muscular movements were reported. Percentages are rounded off to whole number at the nearest single decimal.

    Time frame: Within 6 hours post-surgery (Day 1)

  5. Percentage of Participants With Absence of Nausea in the First 24 Hours Post-Surgery

    Percentage of participants without nausea, defined as urge to vomit without the presence of expulsive muscular movements were reported. CMH method was used for analysis. Percentages are rounded off to whole number at the nearest single decimal.

    Time frame: Within 24 hours post-surgery (up to Day 2)

  6. Percentage of Participants Requiring Rescue Therapy for Breakthrough PONV Within 24 Hours Post-Surgery

    Percentage of participants to whom rescue therapy was given as per local standard of care guidelines were reported. Percentages are rounded off to whole number at the nearest single decimal.

    Time frame: Within 24 hours post-surgery (up to Day 2)

  7. Time From End of Surgery to First Emetic Event

    Duration between end of wound closure to first emetic event i.e., vomiting or retching was reported. If a participant did not have an emetic event within 24 hours post-surgery, they were censored at 24 hours post-surgery. Cox proportional hazard model was used for analysis.

    Time frame: Within 24 hours post-surgery (up to Day 2)

  8. Peak Nausea Verbal Rating Scale (VRS) Score

    VRS was used to score postoperative nausea on 11-point numerical scale. The score ranges from 0-10, where 0 represents 'no nausea' and 10 represents 'worst nausea possible'. Higher score represents worsening of disease. Mixed-effects model for repeated measures (MMRM) was used for analysis. Least square mean (LSM) estimates extracted from MMRM are presented in the data table for each time point.

    Time frame: 30 minutes; 1, 2, 6, and 24 hours post-surgery (up to Day 2)

  9. Percentage of Participants With Total Response

    Percentage of participants with total response, defined as no emesis, no nausea (VRS score \<1), and no need for rescue therapy were reported. VRS was used to score postoperative nausea on 11-point numerical scale, where 0 represents 'no nausea' and 10 represents 'worst nausea possible'. Percentages are rounded off to whole number at the nearest single decimal.

    Time frame: Within 24 hours post-surgery (up to Day 2)

  10. TAK-951 Plasma Concentrations

    Time frame: 1-3, 4-6, 7-9, 10-18, and 22-26 hours post-dose (up to Day 2)

  11. Percentage of Participants With Any Treatment Emergent Adverse Event (TEAE)

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an AE with an onset that occurs after receiving study drug. Percentages are rounded off to whole number at the nearest single decimal.

    Time frame: From first administration of study drug up to Day 14

  12. Percentage of Participants With Markedly Abnormal Vital Signs

    Vital signs included heart rate, respiratory rate, systolic blood pressure (SBP) and diastolic blood pressure (DBP), body temperature and BMI. Percentage of participants with markedly abnormal vital sign values were reported. Percentages are rounded off to whole number at the nearest single decimal. Only categories with at least 1 participant with data are reported.

    Time frame: From first administration of study drug up to Day 14

  13. Percentage of Participants With Clinically Significant Electrocardiogram (ECG)

    Percentage of participants with clinically significant ECG interpretation were reported. Percentages are rounded off to whole number at the nearest single decimal. A combined ECG interpretation was derived using ECG heart rate, PR interval, RR interval, QRS duration, QT interval, and QT interval with Fridericia correction method (QTcF).

    Time frame: From first administration of study drug up to Day 14

  14. Percentage of Participants With Markedly Abnormal Clinical Laboratory Values

    Laboratory parameters included hematology and serum chemistry. Percentage of participants with markedly abnormal clinical laboratory values were reported. Percentages are rounded off to whole number at the nearest single decimal. Only categories with at least 1 participant with data are reported.

    Time frame: From first administration of study drug up to Day 14

  15. Percentage of Participants With TAK-951 Antidrug Antibodies (ADA)

    Percentage of participants with ADA results as: ADA negative, ADA positive were reported. Participants with ADA positive status are defined as those who had confirmed positive ADA status in baseline or at least 1 postbaseline assessments. Participants with ADA negative status are defined as those who did not have positive ADA response at baseline and in all postbaseline assessments.

    Time frame: Within 6 hours post-surgery (Day 1)

07

Results

Posted Apr 21, 2023

Participant flow

Participants took part in the study at 7 sites in the United States from 20 October 2020 to 21 March 2022. Participants with a diagnosis of postoperative nausea and vomiting (PONV) were enrolled in 1:1 ratio.

Participant flow — Overall Study
MilestoneOndansetron 4 mg IVTAK-951 4 mg SC
Started4445
Full analysis set (fas)4139
Pharmacokinetic (pk) set021
Immunogenicity set021
Unintended mis-dose due to dosing error018
Completed3836
Not completed69
Withdrew: Adverse event01
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject21
Withdrew: Reason not specified36

Outcome measures

PrimaryPercentage of Participants With Complete Response in the Immediate Postoperative Period

Percentage of participants with complete response, defined as no emesis (vomiting or retching) and no need for rescue therapy (indicated if vomiting/retching and/or nausea score ≥4 or upon participant's request) were reported. The severity of nausea was scored using a self-reported, 11-point numerical Verbal Rating Scale (VRS), where 0 represents no nausea and 10 represents the worst nausea possible. Significant nausea was defined as a VRS score ≥4. Percentages are rounded off to whole number at the nearest single decimal.

Time frame:
6 hours post-surgery (Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response in the Immediate Postoperative Period
percentage of participantsOndansetron 4 mg IVTAK-951 4 mg SC
Percentage of Participants With Complete Response in the Immediate Postoperative Period48.8 (0.335 to 0.641)71.8 (0.577 to 0.859)
Statistical analysis
  • Ondansetron 4 mg IV vs TAK-951 4 mg SC · Adjusted treatment difference: 0.241 · 95% CI 0.031 to 0.452Adjusted treatment difference between TAK-951, ondansetron, associated confidence intervals: based on CMH method, adjusting for number of Apfel risk factors (3/4), or exact unconditional confidence limits for treatment difference if numerator is ≤5.
SecondaryPercentage of Participants With Complete Response Within 24 Hours Post-Surgery

Percentage of participants with complete response, defined as no emesis (vomiting or retching) and no need for rescue therapy (indicated if vomiting/retching and/or nausea score ≥4 or upon participant's request) were reported. The severity of nausea was scored using a self-reported, 11-point numerical Verbal Rating Scale (VRS), where 0 represents no nausea and 10 represents the worst nausea possible. Significant nausea was defined as a VRS score ≥4. Percentages are rounded off to whole number at the nearest single decimal.

Time frame:
Within 24 hours post-surgery (up to Day 2)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response Within 24 Hours Post-Surgery
percentage of participantsOndansetron 4 mg IVTAK-951 4 mg SC
Percentage of Participants With Complete Response Within 24 Hours Post-Surgery41.5 (0.264 to 0.565)59.0 (0.435 to 0.744)
Statistical analysis
  • Ondansetron 4 mg IV vs TAK-951 4 mg SC · Adjusted treatment difference: 0.175 · 95% CI -0.044 to 0.394
SecondaryPercentage of Participants With Emesis in the First 6 Hours Post-Surgery

Percentage of participants with emesis, defined as vomiting (the forceful discharge of even the smallest amount of stomach contents) or retching (the same muscular movements as vomiting but without expulsion of stomach contents) were reported. Percentages are rounded off to whole number at the nearest single decimal.

Time frame:
Within 6 hours post-surgery (Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Emesis in the First 6 Hours Post-Surgery
percentage of participantsOndansetron 4 mg IVTAK-951 4 mg SC
Percentage of Participants With Emesis in the First 6 Hours Post-Surgery17.1 (0.056 to 0.286)7.7 (0.016 to 0.209)
Statistical analysis
  • Ondansetron 4 mg IV vs TAK-951 4 mg SC · Adjusted treatment difference: -0.094 · 95% CI -0.253 to 0.059Adjusted treatment difference between TAK-951, ondansetron, associated confidence intervals: based on CMH method, adjusting for number of Apfel risk factors (3/4), or exact unconditional confidence limits for treatment difference if numerator is ≤5.
SecondaryPercentage of Participants With Emesis Within 24 Hours Post-Surgery

Percentage of participants with emesis, defined as vomiting (the forceful discharge of even the smallest amount of stomach contents) or retching (the same muscular movements as vomiting but without expulsion of stomach contents) were reported. Percentages are rounded off to whole number at the nearest single decimal.

Time frame:
Within 24 hours post-surgery (up to Day 2)
Reported as:
Number · percentage of participants
Percentage of Participants With Emesis Within 24 Hours Post-Surgery
percentage of participantsOndansetron 4 mg IVTAK-951 4 mg SC
Percentage of Participants With Emesis Within 24 Hours Post-Surgery24.4 (0.112 to 0.375)10.3 (0.029 to 0.242)
Statistical analysis
  • Ondansetron 4 mg IV vs TAK-951 4 mg SC · Adjusted treatment difference: -0.141 · 95% CI -0.316 to 0.033Adjusted treatment difference between TAK-951, ondansetron, associated confidence intervals: based on CMH method, adjusting for number of Apfel risk factors (3/4), or exact unconditional confidence limits for treatment difference if numerator is ≤5.
SecondaryPercentage of Participants With Absence of Nausea in the First 6 Hours Post-Surgery

Percentage of participants without nausea, defined as urge to vomit without the presence of expulsive muscular movements were reported. Percentages are rounded off to whole number at the nearest single decimal.

Time frame:
Within 6 hours post-surgery (Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Absence of Nausea in the First 6 Hours Post-Surgery
percentage of participantsOndansetron 4 mg IVTAK-951 4 mg SC
Percentage of Participants With Absence of Nausea in the First 6 Hours Post-Surgery41.5 (0.264 to 0.565)59.0 (0.435 to 0.744)
Statistical analysis
  • Ondansetron 4 mg IV vs TAK-951 4 mg SC · Adjusted treatment difference: 0.191 · 95% CI -0.029 to 0.410Adjusted treatment difference between TAK-951, ondansetron, associated confidence intervals: based on CMH method, adjusting for number of Apfel risk factors (3/4), or exact unconditional confidence limits for treatment difference if numerator is ≤5.
SecondaryPercentage of Participants With Absence of Nausea in the First 24 Hours Post-Surgery

Percentage of participants without nausea, defined as urge to vomit without the presence of expulsive muscular movements were reported. CMH method was used for analysis. Percentages are rounded off to whole number at the nearest single decimal.

Time frame:
Within 24 hours post-surgery (up to Day 2)
Reported as:
Number · percentage of participants
Percentage of Participants With Absence of Nausea in the First 24 Hours Post-Surgery
percentage of participantsOndansetron 4 mg IVTAK-951 4 mg SC
Percentage of Participants With Absence of Nausea in the First 24 Hours Post-Surgery34.1 (0.196 to 0.487)48.7 (0.330 to 0.644)
Statistical analysis
  • Ondansetron 4 mg IV vs TAK-951 4 mg SC · Adjusted treatment difference: 0.146 · 95% CI -0.073 to 0.365Adjusted treatment difference between TAK-951, ondansetron, associated confidence intervals: based on CMH method, adjusting for number of Apfel risk factors (3/4), or exact unconditional confidence limits for treatment difference if numerator is ≤5.
SecondaryPercentage of Participants Requiring Rescue Therapy for Breakthrough PONV Within 24 Hours Post-Surgery

Percentage of participants to whom rescue therapy was given as per local standard of care guidelines were reported. Percentages are rounded off to whole number at the nearest single decimal.

Time frame:
Within 24 hours post-surgery (up to Day 2)
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Rescue Therapy for Breakthrough PONV Within 24 Hours Post-Surgery
percentage of participantsOndansetron 4 mg IVTAK-951 4 mg SC
Percentage of Participants Requiring Rescue Therapy for Breakthrough PONV Within 24 Hours Post-Surgery56.1 (0.409 to 0.713)33.3 (0.185 to 0.481)
Statistical analysis
  • Ondansetron 4 mg IV vs TAK-951 4 mg SC · Adjusted treatment difference: -0.234 · 95% CI -0.448 to -0.019Adjusted treatment difference between TAK-951, ondansetron, associated confidence intervals: based on CMH method, adjusting for number of Apfel risk factors (3/4), or exact unconditional confidence limits for treatment difference if numerator is ≤5.
SecondaryTime From End of Surgery to First Emetic Event

Duration between end of wound closure to first emetic event i.e., vomiting or retching was reported. If a participant did not have an emetic event within 24 hours post-surgery, they were censored at 24 hours post-surgery. Cox proportional hazard model was used for analysis.

Time frame:
Within 24 hours post-surgery (up to Day 2)
Reported as:
Median · hours
Time From End of Surgery to First Emetic Event
hoursOndansetron 4 mg IVTAK-951 4 mg SC
Time From End of Surgery to First Emetic EventNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Ondansetron 4 mg IV vs TAK-951 4 mg SC · Hazard ratio (hr): 0.393 · 95% CI 0.122 to 1.259The hazard ratio is derived from a Cox proportional hazard model with treatment group and the number of Apfel risk factors (3 or 4) as independent variables.
SecondaryPeak Nausea Verbal Rating Scale (VRS) Score

VRS was used to score postoperative nausea on 11-point numerical scale. The score ranges from 0-10, where 0 represents 'no nausea' and 10 represents 'worst nausea possible'. Higher score represents worsening of disease. Mixed-effects model for repeated measures (MMRM) was used for analysis. Least square mean (LSM) estimates extracted from MMRM are presented in the data table for each time point.

Time frame:
30 minutes; 1, 2, 6, and 24 hours post-surgery (up to Day 2)
Reported as:
Least squares mean · score on a scale
Peak Nausea Verbal Rating Scale (VRS) Score
score on a scaleOndansetron 4 mg IVTAK-951 4 mg SC
30 Minutes Post Surgery0.159 ± 0.2270.347 ± 0.184
1 Hour Post Surgery0.099 ± 0.2540.500 ± 0.204
2 Hours Post Surgery0.043 ± 0.2010.308 ± 0.162
6 Hours Post Surgery-0.020 ± 0.0730.077 ± 0.059
24 Hours Post Surgery0.203 ± 0.1420.000 ± 0.117
Statistical analysis
  • Ondansetron 4 mg IV vs TAK-951 4 mg SC · Difference in lsm estimates: 0.188 · 95% CI -0.402 to 0.777
  • Ondansetron 4 mg IV vs TAK-951 4 mg SC · Difference in lsm estimates: 0.401 · 95% CI -0.258 to 1.059
  • Ondansetron 4 mg IV vs TAK-951 4 mg SC · Difference in lsm estimates: 0.265 · 95% CI 0 to 0.786
  • Ondansetron 4 mg IV vs TAK-951 4 mg SC · Difference in lsm estimates: 0.097 · 95% CI -0.093 to 0.286
  • Ondansetron 4 mg IV vs TAK-951 4 mg SC · Difference in lsm estimates: -0.203 · 95% CI -0.575 to 0.170
SecondaryPercentage of Participants With Total Response

Percentage of participants with total response, defined as no emesis, no nausea (VRS score \<1), and no need for rescue therapy were reported. VRS was used to score postoperative nausea on 11-point numerical scale, where 0 represents 'no nausea' and 10 represents 'worst nausea possible'. Percentages are rounded off to whole number at the nearest single decimal.

Time frame:
Within 24 hours post-surgery (up to Day 2)
Reported as:
Number · percentage of participants
Percentage of Participants With Total Response
percentage of participantsOndansetron 4 mg IVTAK-951 4 mg SC
Percentage of Participants With Total Response34.1 (0.196 to 0.487)48.7 (0.330 to 0.644)
Statistical analysis
  • Ondansetron 4 mg IV vs TAK-951 4 mg SC · Adjusted treatment difference: 0.146 · 95% CI -0.073 to 0.365Adjusted treatment difference between TAK-951, ondansetron, associated confidence intervals: based on CMH method, adjusting for number of Apfel risk factors (3/4), or exact unconditional confidence limits for treatment difference if numerator is ≤5.
SecondaryTAK-951 Plasma Concentrations
Time frame:
1-3, 4-6, 7-9, 10-18, and 22-26 hours post-dose (up to Day 2)
Reported as:
Mean · picograms per milliliter(pg/mL)
TAK-951 Plasma Concentrations
picograms per milliliter(pg/mL)TAK-951 4 mg SCTAK-951 Redacted mg SC
1-3 Hours Post Dose24734.50 ± 14782.35958229.41 ± 42971.281
4-6 Hours Post Dose18456.11 ± 13906.45036950.00 ± 26649.650
7-9 Hours Post Dose10568.31 ± 8140.68417741.76 ± 9705.848
10-18 Hours Post Dose4478.22 ± 2433.185—
22-26 Hours Post Dose672.63 ± 699.161—
SecondaryPercentage of Participants With Any Treatment Emergent Adverse Event (TEAE)

An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an AE with an onset that occurs after receiving study drug. Percentages are rounded off to whole number at the nearest single decimal.

Time frame:
From first administration of study drug up to Day 14
Reported as:
Number · percentage of participants
Percentage of Participants With Any Treatment Emergent Adverse Event (TEAE)
percentage of participantsOndansetron 4 mg IVTAK-951 4 mg SCTAK-951 Redacted mg SC
Percentage of Participants With Any Treatment Emergent Adverse Event (TEAE)87.871.488.9
SecondaryPercentage of Participants With Markedly Abnormal Vital Signs

Vital signs included heart rate, respiratory rate, systolic blood pressure (SBP) and diastolic blood pressure (DBP), body temperature and BMI. Percentage of participants with markedly abnormal vital sign values were reported. Percentages are rounded off to whole number at the nearest single decimal. Only categories with at least 1 participant with data are reported.

Time frame:
From first administration of study drug up to Day 14
Reported as:
Number · percentage of participants
Percentage of Participants With Markedly Abnormal Vital Signs
percentage of participantsOndansetron 4 mg IVTAK-951 4 mg SCTAK-951 Redacted mg SC
Heart Rate (beats per minute [beats/min]): Low: <6036.619.022.2
Heart Rate (beats/min): High: >10014.666.772.2
Respiratory Rate (breaths per minute [breaths/min]): Low: <1246.319.055.6
Respiratory Rate (breaths/min): High: >16100.0100.0100.0
SBP (millimeters of mercury [mmHg]): Low: <857.39.516.7
SBP (mmHg): High: >14070.742.977.8
DBP (mmHg): Low: <5022.033.355.6
DBP (mmHg): High: >9043.914.338.9
BMI (kg/m^2): High: >25.090.285.788.9
SecondaryPercentage of Participants With Clinically Significant Electrocardiogram (ECG)

Percentage of participants with clinically significant ECG interpretation were reported. Percentages are rounded off to whole number at the nearest single decimal. A combined ECG interpretation was derived using ECG heart rate, PR interval, RR interval, QRS duration, QT interval, and QT interval with Fridericia correction method (QTcF).

Time frame:
From first administration of study drug up to Day 14
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Electrocardiogram (ECG)
percentage of participantsOndansetron 4 mg IVTAK-951 4 mg SCTAK-951 Redacted mg SC
Percentage of Participants With Clinically Significant Electrocardiogram (ECG)2.40.00.0
SecondaryPercentage of Participants With Markedly Abnormal Clinical Laboratory Values

Laboratory parameters included hematology and serum chemistry. Percentage of participants with markedly abnormal clinical laboratory values were reported. Percentages are rounded off to whole number at the nearest single decimal. Only categories with at least 1 participant with data are reported.

Time frame:
From first administration of study drug up to Day 14
Reported as:
Number · percentage of participants
Percentage of Participants With Markedly Abnormal Clinical Laboratory Values
percentage of participantsOndansetron 4 mg IVTAK-951 4 mg SCTAK-951 Redacted mg SC
Erythrocytes (10^12 per liter [10^12/L]): Low: <0.8*Lower Limit of Normal (LLN)14.614.327.8
Hemoglobin (grams per liter [g/L]): Low: <0.8*LLN14.623.811.1
Hematocrit (percent [%]): Low: <0.8*LLN12.223.811.1
Aspartate Aminotransferase (units per liter[U/L]): High: >3*Upper Limit of Normal (ULN)0.04.80.0
Alanine Aminotransferase (U/L): High: >3*ULN0.04.80.0
Albumin (g/L): Low: <250.04.80.0
Protein (g/L): Low: <0.8*LLN2.44.816.7
Gamma Glutamyl Transferase (U/L): High: >3*ULN0.05.00.0
Glucose (millimoles per liter [mmol/L]): Low: <30.04.80.0
Glucose (millimoles per liter [mmol/L]): High: >104.90.00.0
Potassium (mmol/L): High: >5.52.40.00.0
SecondaryPercentage of Participants With TAK-951 Antidrug Antibodies (ADA)

Percentage of participants with ADA results as: ADA negative, ADA positive were reported. Participants with ADA positive status are defined as those who had confirmed positive ADA status in baseline or at least 1 postbaseline assessments. Participants with ADA negative status are defined as those who did not have positive ADA response at baseline and in all postbaseline assessments.

Time frame:
Within 6 hours post-surgery (Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With TAK-951 Antidrug Antibodies (ADA)
percentage of participantsTAK-951 4 mg SCTAK-951 Redacted mg SC
Any Antidrug Antibody Positive0.00.0
Any Antidrug Antibody Negative100.0100.0

Adverse events

Collected over From first administration of study drug up to Day 14. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ondansetron 4 mg IV0/41 (0%)0/41 (0%)36/41 (87.8%)
TAK-951 4 mg SC0/21 (0%)0/21 (0%)15/21 (71.4%)
TAK-951 Redacted mg SC0/18 (0%)0/18 (0%)16/18 (88.9%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventOndansetron 4 mg IVTAK-951 4 mg SCTAK-951 Redacted mg SC
Sinus tachycardiaCardiac disorders4/416/2110/18
Procedural hypotensionInjury, poisoning and procedural complications16/418/216/18
HypotensionVascular disorders3/411/217/18
FlatulenceGastrointestinal disorders6/416/211/18
TachypnoeaRespiratory, thoracic and mediastinal disorders6/410/214/18
TachycardiaCardiac disorders0/410/213/18
HypertensionVascular disorders1/410/212/18
BradycardiaCardiac disorders4/410/210/18
ChillsGeneral disorders1/412/210/18
PruritusSkin and subcutaneous tissue disorders1/411/211/18

Baseline characteristics

FAS included all participants who were randomized to treatment and received both doses of double-blind study drug before and during surgery.

Age, Continuous
Age, Continuous(years)Ondansetron 4 mg IVTAK-951 4 mg SCTotal
Mean46.0 ± 10.3245.1 ± 10.5745.6 ± 10.39
Sex: Female, Male
Sex: Female, Male(Participants)Ondansetron 4 mg IVTAK-951 4 mg SCTotal
Female383876
Male314
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ondansetron 4 mg IVTAK-951 4 mg SCTotal
Hispanic or Latino8917
Not Hispanic or Latino332962
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ondansetron 4 mg IVTAK-951 4 mg SCTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American81018
White312758
More than one race000
Unknown or Not Reported213
Region of Enrollment
Region of Enrollment(Participants)Ondansetron 4 mg IVTAK-951 4 mg SCTotal
United States413980
Weight
Weight(kg)Ondansetron 4 mg IVTAK-951 4 mg SCTotal
Mean93.85 ± 27.43987.61 ± 22.25890.81 ± 25.087
Height
Height(cm)Ondansetron 4 mg IVTAK-951 4 mg SCTotal
Mean164.57 ± 8.448164.32 ± 9.499164.44 ± 8.919
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Ondansetron 4 mg IVTAK-951 4 mg SCTotal
Mean34.41 ± 8.90932.47 ± 7.57433.47 ± 8.290
08

Study locations

7 sites
  • Helen Keller Hospital
    Sheffield, Alabama 35660, United States
  • Lotus Clinical Research Inc
    Pasadena, California 91105, United States
  • Phoenix Clinical Research
    Tamarac, Florida 33321, United States
  • Stony Brook Medicine - Hospital
    Stony Brook, New York 11794, United States
  • First Street Hospital - Research
    Bellaire, Texas 77401, United States
  • Legent Orthopedic Hospital
    Carrollton, Texas 75006, United States
  • Altus Houston Hospital - Hospital
    Houston, Texas 77072, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Mar 2022, 16 months.

Results were first posted in Apr 2023, 1 year 1 month after primary completion.

Of 17 phase 2 interventional studies under Postoperative Nausea and Vomiting, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 29. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2020
First posted
Sep 21, 2020
StartActual
Oct 20, 2020
Primary completionActual
Mar 7, 2022
CompletionActual
Mar 21, 2022
Results first posted
Apr 21, 2023
Last update
Apr 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04557189
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Sep 21, 2020
Start date
Oct 20, 2020
Primary completion
Mar 7, 2022
Completion
Mar 21, 2022
Results posted
Apr 21, 2023
Last update
Apr 21, 2023

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: TAK-951 · Ondansetron

Start the discussion